{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:16:02Z","timestamp":1790727362580,"version":"4.1.0"},"reference-count":46,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Cutaneous Lymphoma Catalyst Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The rat protoparvovirus H-1 (H-1PV) is an oncolytic virus known for its anticancer properties in laboratory models of various human tumors, including non-Hodgkin lymphomas (NHL) of B-cell origin. However, H-1PV therapeutic potential against hematological malignancies of T-cell origin remains underexplored. The aim of the present study was to conduct a pilot preclinical investigation of H-1PV-mediated oncolytic effects in cutaneous T-cell lymphoma (CTCL), a type of NHL that is urgently calling for innovative therapies. We demonstrated H-1PV productive infection and induction of oncolysis in both classically grown CTCL suspension cultures and in a novel, in vivo-relevant, heterotypic spheroid model, but not in healthy donor controls, including peripheral blood mononuclear cells (PBMCs). H-1PV-mediated oncolysis of CTCL cells was not prevented by Bcl-2 overexpression and was accompanied by increased extracellular ATP release. In CTCL spheroid co-cultures with PBMCs, increased spheroid infiltration with immune cells was detected upon co-culture treatment with the virus. In conclusion, our preclinical data show that H-1PV may hold significant potential as an ingenious viroimmunotherapeutic drug candidate against CTCL.<\/jats:p>","DOI":"10.3390\/cancers16152711","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T15:25:23Z","timestamp":1722353123000},"page":"2711","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["H-1 Parvovirus-Induced Oncolysis and Tumor Microenvironment Immune Modulation in a Novel Heterotypic Spheroid Model of Cutaneous T-Cell Lymphoma"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2349-0404","authenticated-orcid":false,"given":"Assia","family":"Angelova","sequence":"first","affiliation":[{"name":"Clinical Cooperation Unit Virotherapy, Infection, Inflammation and Cancer Program, German Cancer Research Center, 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Barf","sequence":"additional","affiliation":[{"name":"Clinical Cooperation Unit Virotherapy, Infection, Inflammation and Cancer Program, German Cancer Research Center, 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Just","sequence":"additional","affiliation":[{"name":"Clinical Cooperation Unit Virotherapy, Infection, Inflammation and Cancer Program, German Cancer Research Center, 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Leuchs","sequence":"additional","affiliation":[{"name":"Biopharmaceutical Production and Development Unit, German Cancer Research Center, 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2614-2651","authenticated-orcid":false,"given":"Jean","family":"Rommelaere","sequence":"additional","affiliation":[{"name":"Clinical Cooperation Unit Virotherapy, Infection, Inflammation and Cancer Program, German Cancer Research Center, 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Ungerechts","sequence":"additional","affiliation":[{"name":"Clinical Cooperation Unit Virotherapy, Infection, Inflammation and Cancer Program, German Cancer Research Center, 69120 Heidelberg, Germany"},{"name":"Department of Medical Oncology, National Center for Tumor Diseases Heidelberg and Heidelberg University Hospital, 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of research and Treatment of Cancer (EORTC)","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"223.e1","DOI":"10.1016\/j.jaad.2013.08.033","article-title":"Primary cutaneous T-cell lymphoma (mycosis fungoides and S\u00e9zary syndrome): Part II. Prognosis, management, and future directions","volume":"70","author":"Jawed","year":"2014","journal-title":"J. Am. Acad. Derm."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1182\/blood-2011-08-376319","article-title":"Prognostic factors in transformed mycosis fungoides: A retrospective analysis of 100 cases","volume":"119","author":"Benner","year":"2012","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/ajh.26299","article-title":"Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management","volume":"96","author":"Hristov","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2217\/imt.15.35","article-title":"Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma","volume":"7","author":"Johnson","year":"2015","journal-title":"Immunotherapy"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5501\/wjv.v10.i5.229","article-title":"Oncolytic virus therapy in cancer: A current review","volume":"10","author":"Apolonio","year":"2021","journal-title":"World J. Virol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1038\/sj.jid.5700529","article-title":"Recombinant measles virus induces cytolysis of cutaneous T-cell lymphoma in vitro and in vivo","volume":"126","author":"Oberholzer","year":"2006","journal-title":"J. Investig. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1182\/blood-2004-11-4558","article-title":"Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells","volume":"106","author":"Heinzerling","year":"2005","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1128\/JVI.03416-12","article-title":"Structural characterization of H-1 parvovirus: Comparison of infectious virions to empty capsids","volume":"87","author":"Halder","year":"2013","journal-title":"J. Virol."},{"key":"ref_10","first-page":"305","article-title":"A virus associated with transplantable human tumors","volume":"37","author":"Toolan","year":"1961","journal-title":"Bull. N. Y. Acad. Med."},{"key":"ref_11","first-page":"2552","article-title":"Inhibition of 7,12-dimethylbenz(a)anthracene-induced tumors in Syrian hamsters by prior infection with H-1 parvovirus","volume":"42","author":"Toolan","year":"1982","journal-title":"Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/0042-6822(68)90226-2","article-title":"Inhibition of the incidence of tumors produced by adenovirus 12 in hamsters","volume":"35","author":"Toolan","year":"1968","journal-title":"Virology"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Bretscher, K., and Marchini, A. (2019). H-1 parvovirus as a cancer-killing agent: Past, present, and future. Viruses, 11.","DOI":"10.3390\/v11060562"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1016\/j.ymthe.2017.08.016","article-title":"Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I\/IIa glioblastoma trial","volume":"25","author":"Geletneky","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1158\/1078-0432.CCR-21-1020","article-title":"Phase 2 trial of oncolytic H-1 parvovirus therapy shows safety and signs of immune system activation in patients with metastatic pancreatic ductal adenocarcinoma","volume":"27","author":"Hajda","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/mt.2009.78","article-title":"Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: In vitro and in vivo studies","volume":"17","author":"Angelova","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Angelova, A.L., Witzens-Harig, M., Galabov, A.S., and Rommelaere, J. (2017). The oncolytic virotherapy era in cancer management: Prospects of applying H-1 parvovirus to treat blood and solid cancers. Front. Oncol., 7.","DOI":"10.3389\/fonc.2017.00093"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Tessmer, C., Plotzky, C., Fees, J., Welsch, H., Eudenbach, R., Faber, M., Sim\u00f3n, A., Angelova, A., Rommelaere, J., and Hofmann, I. (2022). Generation and validation of monoclonal antibodies suitable for detecting and monitoring parvovirus infections. Pathogens, 11.","DOI":"10.3390\/pathogens11020208"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1089\/ten.tec.2015.0280","article-title":"Generation of homogeneous three-dimensional pancreatic cancer cell spheroids using an improved hanging drop technique","volume":"22","author":"Ware","year":"2016","journal-title":"Tissue Eng. Part C Methods"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jviromet.2015.11.022","article-title":"Standardized large-scale H-1PV production process with efficient quality and quantity monitoring","volume":"229","author":"Leuchs","year":"2016","journal-title":"J. Virol. Methods"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1128\/JVI.77.6.3851-3858.2003","article-title":"Chimeric and pseudotyped parvoviruses minimize the contamination of recombinant stocks with replication-competent viruses and identify a DNA sequence that restricts parvovirus H-1 in mouse cells","volume":"77","author":"Wrzesinski","year":"2003","journal-title":"J Virol"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.4161\/cbt.10.12.13455","article-title":"Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent","volume":"10","author":"Grekova","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1684\/ejd.2018.3400","article-title":"Increased HMGB1 levels in lesional skin and sera in patients with cutaneous T-cell lymphoma","volume":"28","author":"Senda","year":"2018","journal-title":"Eur. J. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1046\/j.1523-1747.2002.19610.x","article-title":"Increased CCR4 expression in cutaneous T cell lymphoma","volume":"119","author":"Ferenczi","year":"2002","journal-title":"J. Investig. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/eji.202049043","article-title":"CCR4 in cutaneous T-cell lymphoma: Therapeutic targeting of a pathogenic driver","volume":"51","author":"Nicolay","year":"2021","journal-title":"Eur. J. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e142067","DOI":"10.1172\/jci.insight.142067","article-title":"Cytokinocytes: The diverse contribution of keratinocytes to immune responses in skin","volume":"5","author":"Jiang","year":"2020","journal-title":"JCI Insight"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1126\/science.abk3436","article-title":"Oncolytic virotherapy as immunotherapy","volume":"374","author":"Melcher","year":"2021","journal-title":"Science"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"El-Serafi, A.T., El-Serafi, I., Steinvall, I., Sj\u00f6berg, F., and Elmasry, M. (2022). A systematic review of keratinocyte secretions: A regenerative perspective. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23147934"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00403-020-02062-5","article-title":"The polymorphisms of IL-6\/STAT3 signaling pathway may contribute to cutaneous T-cell lymphomas susceptibility","volume":"313","author":"Olszewska","year":"2021","journal-title":"Arch. Dermatol. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: Basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/blood.2019001545","article-title":"Combined inhibition of Bcl-2 and NFkB synergistically induces cell death in cutaneous T-cell lymphoma","volume":"134","author":"Froehlich","year":"2019","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1182\/blood-2017-06-792150","article-title":"Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients","volume":"130","author":"Cyrenne","year":"2017","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Moral\u00e8s, O., Richard, A., Martin, N., Mrizak, D., S\u00e9n\u00e9chal, M., Miroux, C., Pancr\u00e9, V., Rommelaere, J., Caillet-Fauquet, P., and de Launoit, Y. (2012). Activation of a helper and not regulatory human CD4+ T cell response by oncolytic H-1 parvovirus. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0032197"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.virol.2013.09.019","article-title":"Capacity of wild-type and chemokine-armed parvovirus H-1PV for inhibiting neo-angiogenesis","volume":"447","author":"Lavie","year":"2013","journal-title":"Virology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5263","DOI":"10.1128\/JVI.03688-13","article-title":"Complementary induction of immunogenic cell dedath by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer","volume":"88","author":"Angelova","year":"2014","journal-title":"J Virol"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/sj.jid.5700530","article-title":"Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9","volume":"127","author":"Lebre","year":"2007","journal-title":"J. Investig. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.1038\/onc.2010.292","article-title":"Extracellular adenosine triphosphate and adenosine in cancer","volume":"29","author":"Stagg","year":"2010","journal-title":"Oncogene"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1182\/blood.V99.2.706","article-title":"P2X7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia","volume":"99","author":"Adinolfi","year":"2002","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.canlet.2007.10.025","article-title":"Expression and function of the P2X(7) receptor in rat C6 glioma cells","volume":"260","author":"Wei","year":"2008","journal-title":"Cancer Lett."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1007\/s00018-011-0735-1","article-title":"Vimentin in cancer and its potential as a molecular target for cancer therapy","volume":"68","author":"Satelli","year":"2011","journal-title":"Cell Mol. Life Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1038\/s41388-023-02703-9","article-title":"Vimentin is required for tumor progression and metastasis in a mouse model of non-small cell lung cancer","volume":"42","author":"Berr","year":"2023","journal-title":"Oncogene"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41408-019-0197-5","article-title":"High intratumoral expression of vimentin predicts histological transformation in patients with follicular lymphoma","volume":"9","author":"Madsen","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3109\/10428194.2010.551793","article-title":"Akt, 14-3-3\u03b6 and vimentin mediate a drug-resistant invasive phenotype in diffuse large B-cell lymphoma","volume":"52","author":"Maxwell","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/ncb1355","article-title":"Vimentin function in lymphocyte adhesion and transcellular migration","volume":"8","author":"Nieminen","year":"2006","journal-title":"Nature Cell Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1111\/jth.14976","article-title":"Von Willebrand factor and cancer; metastasis and coagulopathies","volume":"18","author":"Patmore","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.cyto.2008.07.472","article-title":"CCR4 and CCR10 are expressed on epidermal keratinocytes and are involved in cutaneous immune reaction","volume":"44","author":"Fujimoto","year":"2008","journal-title":"Cytokine"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/15\/2711\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:26:44Z","timestamp":1760110004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/15\/2711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":46,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["cancers16152711"],"URL":"https:\/\/doi.org\/10.3390\/cancers16152711","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,30]]}}}